LONDON–(BUSINESS WIRE)– #OrbitSDS–Gyroscope announces that the U.S. Food & Drug Administration (FDA) has granted 510(k) clearance for the Orbit Subretinal Delivery System.
Author: Business Wire
Analysis on Impact of COVID-19: Iris Recognition Market 2020-2024 | The Growing Need To Reduce Identity Duplication to boost the Market Growth | Technavio
LONDON–(BUSINESS WIRE)– #GlobalIrisRecognitionMarket–The Global Iris Recognition Market will grow by $ 2.08 bn during 2020-2024
Zenni Debuts Its First Eyewear Industry Collaboration with Designers Coco and Breezy
NOVATO, Calif.–(BUSINESS WIRE)–Zenni, the DTC eyewear industry leader, is partnering with premium eyewear designers Coco and Breezy for a first-of-its-kind affordable collection for kids. Available exclusively at Zenni.com/planetcb starting today, Pl…
NovaBay Appoints CEO Justin Hall to its Board of Directors
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the appointment of President and CEO Justin Hall to the Company’s board of directors, effective August 21, 2020. Mr. Hall has been with NovaBay for seven…
Soft Contact Lens Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Rising Prevalence of Eye Disorders to Boost Market Growth | Technavio
LONDON–(BUSINESS WIRE)– #GlobalSoftContactLensMarket–The Global Soft Contact Lens Market will grow by $ 1.71 bn during 2020-2024
Global Phacoemulsification Market Outlook to 2027 with Profiles of Major Players Bausch Health Companies, Carl Zeiss Meditec, Alcon, Johnson & Johnson, Nidek Co, and Novartis – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Phacoemulsification Market (By Products – Phacoemulsification Systems & Phacoemulsification Consumables; By Region – North America, Europe & Asia Pacific) Market Outlook 2027” report has been added to Resear…
Kubota Vision Receives Orphan Products Clinical Trials Grants to Emixustat for Stargardt Disease
SEATTLE–(BUSINESS WIRE)–Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that the U.S. Food and Drug Administration (FDA…
Alcon and Actress Katherine McNamara Encourage Consumers to See What Happens with PRECISION1® Contact Lenses
FORT WORTH, Texas–(BUSINESS WIRE)–Alcon and Actress Katherine McNamara Encourage Consumers to See What Happens with PRECISION1® Contact Lenses
Notal Vision Diagnostic Clinic Implements XIFIN RPM to Improve Claim Accuracy, Timely Reimbursement and Patient Experience
SAN DIEGO–(BUSINESS WIRE)–Today, XIFIN has announced a collaboration with Notal Vision Diagnostic Clinic, a leading healthcare provider of ophthalmic remote patient monitoring services, to improve claim accuracy and timely reimbursement. By adopting …
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-125 by Intravitreal Injection for the Treatment of X-Linked Retinitis Pigmentosa
EMERYVILLE, Calif.–(BUSINESS WIRE)–4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced that the first patient has been dosed in the Phase 1/2 clini…
Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies
SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics begins first clinical trial of regenerative treatment for patients with corneal endothelial dystrophies
Genentech and Regeneron Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Combination for COVID-19
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that Genentech and Roche are joining forces with Regeneron in the fight against COVID-19 to develop, manufacture and dist…
Alcon Reports Second Quarter 2020 Results
GENEVA–(BUSINESS WIRE)–Alcon Reports Second Quarter 2020 Results
Outlook into the Worldwide Contact Lens Solution Market to 2025 – North America is Anticipated to Have Significant Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Contact Lens Solution Market – Growth, Trends, and Forecast (2020 – 2025)” report has been added to ResearchAndMarkets.com’s offering. The market for contact lens solutions is growing at a significant rate. The growth is a…
NovaBay Expands Avenova’s Online Distribution
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay expands Avenova’s online distribution to include Walmart.com
Enspryng (satralizumab) de Chugai reçoit l'approbation réglementaire de la FDA pour le trouble du spectre de la neuromyélite optique
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé que la Food and Drug Administration (FDA) des États-Unis a approuvé l’anticorps monoclonal anti-récepteur de l’il-6 humanisé présentant une liaison dépendante du PH, Enspr…
FDA核准中外製藥的Enspryng (Satralizumab)用於泛視神經脊髓炎
東京–(BUSINESS WIRE)–(美國商業資訊)–中外製藥株式會社(Chugai Pharmaceutical Co., Ltd., TOKYO: 4519)宣布，美國食品藥品管理局(FDA)已核准中外製藥研製的pH依賴性結合型人類化抗IL-6受體單株抗體Enspryng™（美國通用名稱：satralizumab-mwge）（下稱Enspryng）用於治療抗水通道蛋白-4 (AQP4)抗體陽性的泛視神經脊髓炎(NMOSD)成人患者。Enspryng為每4週一次皮下給藥**。Enspryn…
Resumen: Enspryng (satralizumab) de Chugai recibe la aprobación normativa de la FDA para el trastorno del espectro de la neuromielitis óptica
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKIO: 4519) ha anunciado que la Administración de Alimentos y Fármacos de Estados Unidos (FDA) ha aprobado el anticuerpo monoclonal humanizado vinculante anti-receptor IL-6 dependiente del pH, E…
Samenvatting: Chugai Enspryng (Satralizumab) ontvangt regelgevende goedkeuring van de FDA voor neuromyelitis optica spectrum disorder
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) heeft aangekondigd dat de Amerikaanse Food en Drug Administration (FDA) het pH-afhankelijke bindende gehumaniseerde monoklonale antilichaam tegen IL-6-receptor, Enspryng ™ ( Amerikaa…
Enspryng (Satralizumab) von Chugai erhält FDA-Zulassung für Neuromyelitis-optica-Spektrum-Erkrankungen
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKIO: 4519), hat bekannt gegeben, dass die US-amerikanische Food and Drug Administration (FDA) den von Chugai entwickelten monoklonalen Anti-IL-6-Rezeptor-Antikörper Enspryng™ (generischer Name …